CRVS News

The US IPO market in the 1Q16 hit its lowest levels since the depths of the financial crisis in 2008/2009. Not a single deal priced outside of the health care sector, where eight deals managed to raise $0.7 billion thanks to substantial buying by their existing ...read more

One biotech IPO priced this week; one remains on the calendar Backed by a well-regarded management team, checkpoint inhibitor developer Corvus Pharmaceuticals (CRVS) raised $71 million. Insiders OrbiMed, Novo, Adams Street and Fidelity, who...read more

Corvus Pharmaceuticals, which is developing checkpoint inhibitors to treat solid tumors, raised $71 million by offering 4.7 million shares at $15, the low end of the range of $15 to $17. Corvus Pharmaceuticals plans to list on the Nasdaq under the symbol CRVS....read more

Corvus Pharmaceuticals is the only IPO on the calendar during the shortened holiday week. Since reaching a year-to-date low on February 11, the S&P 500 has gained 12%, while the market cap-weighted Renaissance IPO Index has surged 19%. The VIX...read more